Taysha Gene Therapies
TSHA
51 hedge funds and large institutions have $475M invested in Taysha Gene Therapies in 2020 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 19 closing their positions.
30% more capital invested
Capital invested by funds: $367M → $475M (+$109M)
26% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 19
11% more funds holding
Funds holding: 46 → 51 (+5)
1.36% more ownership
Funds ownership: 46.3% → 47.67% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.4M |
| 3 |
BlackRock
New York
|
+$8.39M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.53M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$8.37M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.51M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$4.48M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$4.28M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.02M |
TSHA Hedge Fund Activity: Q4 2020 in Review
51 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q4 2020, worth a combined $475M — up 30% from $367M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new TSHA positions and 19 closed out — a net gain of 5 holders — while 8 added to existing stakes and 9 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $31.4M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $8.37M sold.
- 51 institutional investors held Taysha Gene Therapies (TSHA) as of Q4 2020, up from 46 in Q3 2020.
- Funds reported $475M of Taysha Gene Therapies stock for Q4 2020, up 30% quarter-over-quarter.
- 24 funds opened new Taysha Gene Therapies positions in Q4 2020 and 19 closed out, a net change of +5 holders.
- The largest Taysha Gene Therapies buyer in Q4 2020 was Fidelity Investments, an estimated $31.4M added.
- The largest Taysha Gene Therapies seller in Q4 2020 was Sectoral Asset Management, an estimated $8.37M sold.
Based on aggregated 13F filings for Q4 2020.